The SafeBoosC II randomized trial: treatment guided by near-infrared spectroscopy reduces cerebral hypoxia without changing early biomarkers of brain injury

BACKGROUND: The SafeBoosC phase II multicentre randomized clinical trial investigated the benefits and harms of monitoring cerebral oxygenation by near-infrared spectroscopy (NIRS) combined with an evidence-based treatment guideline vs. no NIRS data and treatment as usual in the control group during...

Descripción completa

Detalles Bibliográficos
Autores principales: Plomgaard, Anne M., van Oeveren, Wim, Petersen, Tue H., Alderliesten, Thomas, Austin, Topun, van Bel, Frank, Benders, Manon, Claris, Olivier, Dempsey, Eugene, Franz, Axel, Fumagalli, Monica, Gluud, Christian, Hagmann, Cornelia, Hyttel-Sorensen, Simon, Lemmers, Petra, Pellicer, Adelina, Pichler, Gerhard, Winkel, Per, Greisen, Gorm
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840238/
https://www.ncbi.nlm.nih.gov/pubmed/26679155
http://dx.doi.org/10.1038/pr.2015.266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840238/
https://www.ncbi.nlm.nih.gov/pubmed/26679155
http://dx.doi.org/10.1038/pr.2015.266

Ejemplares similares